Vertex and CRISPR Therapeutics announced authorization of first CRISPR/Cas9 gene-edited therapy by UK MHRA for treatment of Sickle Cell Disease
On Nov. 16, 2023, Vertex and CRISPR Therapeutics announced that the United Kingdom (U.K.) Medicines and Healthcare products…